BRAF is the most frequently mutated gene in melanoma. Constitutive activation of mutant BRAFV600E leads to aberrant Ras-independent MAPK signaling and cell transformation. Inhibition of mutant BRAF is a current frontline therapy for such cases, with improved survival compared with chemotherapy. Unfortunately, reactivation of MAPK signaling by several mechanisms has been shown to cause drug resistance and disease recurrence. In this work, we describe the co-occurrence of an in-frame deletion within an amplified BRAFV600E locus and a missense point mutation of the transcriptional repressor BCORL1 in vemurafenib-resistant A375 melanoma cells. Functional data confirmed that truncated p47BRAFV600E and mutant BCORL1Q1076H both contribute to resistance. Interestingly, either endogenous BCORL1 silencing or ectopic BCORL1Q1076H expression mimicked the effects of a CRISPR/Cas9-edited BCORL1Q1076H locus, suggesting a complex mixture of loss- and gain-of-function effects caused by the mutation. Transcriptomic data confirmed this hypothesis. Finally, we show that the pan-RAF inhibitor sorafenib is not affected by expression of BRAF deletion variant and effectively synergizes with vemurafenib to block resistant cells, suggesting a possible intervention for this class of mutants.

Mologni, L., Costanza, M., Sharma, G., Viltadi, M., Massimino, L., Citterio, S., et al. (2018). Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. NEOPLASIA, 20(5), 467-477 [10.1016/j.neo.2018.02.009].

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells

Mologni, L
Primo
;
Sharma, GG;Viltadi, M;Massimino, L;Citterio, S;Purgante, S;Raman, H;Pirola, A;Piazza, R;Gambacorti-Passerini, C
Ultimo
2018

Abstract

BRAF is the most frequently mutated gene in melanoma. Constitutive activation of mutant BRAFV600E leads to aberrant Ras-independent MAPK signaling and cell transformation. Inhibition of mutant BRAF is a current frontline therapy for such cases, with improved survival compared with chemotherapy. Unfortunately, reactivation of MAPK signaling by several mechanisms has been shown to cause drug resistance and disease recurrence. In this work, we describe the co-occurrence of an in-frame deletion within an amplified BRAFV600E locus and a missense point mutation of the transcriptional repressor BCORL1 in vemurafenib-resistant A375 melanoma cells. Functional data confirmed that truncated p47BRAFV600E and mutant BCORL1Q1076H both contribute to resistance. Interestingly, either endogenous BCORL1 silencing or ectopic BCORL1Q1076H expression mimicked the effects of a CRISPR/Cas9-edited BCORL1Q1076H locus, suggesting a complex mixture of loss- and gain-of-function effects caused by the mutation. Transcriptomic data confirmed this hypothesis. Finally, we show that the pan-RAF inhibitor sorafenib is not affected by expression of BRAF deletion variant and effectively synergizes with vemurafenib to block resistant cells, suggesting a possible intervention for this class of mutants.
Articolo in rivista - Articolo scientifico
BCORL1, BRAF, Melanoma
English
2018
20
5
467
477
open
Mologni, L., Costanza, M., Sharma, G., Viltadi, M., Massimino, L., Citterio, S., et al. (2018). Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. NEOPLASIA, 20(5), 467-477 [10.1016/j.neo.2018.02.009].
File in questo prodotto:
File Dimensione Formato  
Concomitant BCORL1 and BRAF mutations in Vemurafenib-resistant melanoma cells.pdf

accesso aperto

Tipologia di allegato: Author’s Accepted Manuscript, AAM (Post-print)
Dimensione 2.48 MB
Formato Adobe PDF
2.48 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/205002
Citazioni
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
Social impact